DXB

DIMERIX FPO [DXB]
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Healthcare · ASX Small Cap
$0.2400 +2.1%

Updated 14 Jul 2026 · Signals refresh every scan

Get alerts when DXB triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track DXB — Free

Active Signals

Bullish Signals

  • Watch out — volume is flowing out even as price holds up. Distribution pattern
  • Beating the Small Ords index — relative strength of 1.36, so it's outpacing the pack
  • Cash positive / operating cashflow positive
  • 4C filed 2026-04-29
  • Strong revenue growth (+636%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (15% of range)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 64% over the past year
  • Revenue growing at +636% — the top line is moving in the right direction
  • Beneish M-Score 7.74 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-220%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-2.44%/day)
Ask Scout AI about DXB
"What's driving DXB today?" "How does DXB compare to peers?" "Key risks for DXB?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE DMX-200 Available To Patients Via Post-Trial Access Pathways
NONE Dimerix Investor Webinar
NONE Dimerix Licenses DMX200 to Everest for China and Asia Region
NEGATIVE Trading Halt

Recent ASX Announcements

2026-07-08 DMX-200 Available To Patients Via Post-Trial Access Pathways PRICE SENSITIVE
2026-06-16 Dimerix Investor Webinar
2026-06-16 Dimerix Licenses DMX200 to Everest for China and Asia Region PRICE SENSITIVE
2026-06-14 Trading Halt PRICE SENSITIVE

Key Metrics

$141.1M
Market Cap
3.2M
Avg Volume
0.5x
Vol Ratio
$0.16 — $0.67
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-594.5%
ROE
-219.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardlaggardRS: -22
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

109 tickers in this sector

View all Healthcare signals →
Related Tickers
ECS -20.0%MEM -12.5%NTI +12.5%VBS +11.4%BDX +11.0%
Compare:DXB vs ECSDXB vs MEMDXB vs NTI
Scout Pro — Deeper Analysis for DXB
Try Pro free for 30 days
Share this analysis

Track DXB and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required